Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese Subjects
NCT07422142 is registered in ClinicalTrials.gov with Kunming Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese Subjects
- Lead sponsor
- Kunming Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- March 1, 2026
- Completion date
- September 30, 2026
- Enrollment
- 54 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.